Interventional cardiology in a whole new light

Open menu

News & Events

OPSENS – FIRST USE OF dPR FOR THE DIAGNOSIS OF CORONARY STENOSIS WITH THE HEART AT REST

8 November 2018

Quebec City, Quebec, November 8, 2018 – Opsens Inc. (“Opsens”) (TSX:OPS) (OTCQX:OPSSF) announces that its Diastolic Pressure Ratio called dPR, has been used for the first time by Dr. Hitoshi Matsuo, cardiologist and President of the Gifu Heart Center Japan. The measurement of Fractional Flow Reserve (“FFR”) as a method of assessing intracoronary pressure has gained credibility and popularity…

Read more

OPSENS – 50,000 PATIENTS DIAGNOSED WITH THE OPTOWIRE

1 November 2018

Quebec City, Quebec, November 1st, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) has reached an important milestone with more than 50,000 patients assessed with the OptoWire™, a pressure guidewire used to measure Fractional Flow Reserve (“FFR”) to diagnose and treat cardio vascular disease. The use of pressure guidewires to measure FFR for…

Read more

OPSENS TO HOST INVESTOR WEBINAR ON THURSDAY, OCTOBER 4 TO PROVIDE UPDATE ON RECENT DEVELOPMENTS

3 October 2018

OPSENS TO HOST INVESTOR WEBINAR ON THURSDAY, OCTOBER 4 TO PROVIDE UPDATE ON RECENT DEVELOPMENTS Quebec City, Quebec, October 3, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) will host an investor webinar and live Q&A session on Thursday, October 4, 2018, at 4.05 p.m. EST. The webinar will feature a presentation by…

Read more

OPSENS – NEW PRODUCT FOR THE DIAGNOSIS OF CORONARY STENOSIS WITH THE HEART AT REST

20 September 2018

Quebec City, Quebec, September 20, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) announces it has developed a product that will allow the diagnosis of coronary heart blockages with the heart at rest. Filing for regulatory approvals has been completed in targeted territories. Opsens plans to begin commercialization by the end of calendar…

Read more

VISIT OPSENS AT TCT 2018

4 August 2018

Learn more about the benefits of OptoWire® as a workhorse wire at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 Conference by visiting Opsens at their booth (#1907) or attend the complimentary educational lunch symposium. RSVP Now!  Educational Lunch Symposium “FFR and Non-Hyperemic Pressure Ratios: Start Right, Finish Right” Sponsored by Opsens Medical Sunday, September 23, 2018 11:30 a.m. – 12:30 p.m. Presentation…

Read more

OPSENS REPORTS Q3 2018 RESULTS – Quarterly Revenues Eclipse $6.4 M

12 July 2018

Quebec City, Quebec, July 12, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the third quarter ended May 31, 2018. Highlights for the quarter Consolidated revenues reached $6,398,000 for the three-month period compared with $4,892,000 for the same period last year, an increase of $1,506,000 or 31%; Consolidated…

Read more

VISIT OPSENS AT THE CARDIOVASCULAR INNOVATIONS 2018 CONFERENCE

3 July 2018

Learn more about the benefits of OptoWire® as a workhorse wire at the Cardiovascular Innovations (CVI) 2018 Conference by visiting us at the Opsens booth (#T4) or attend the complimentary educational lunch symposium with live case transmission sponsored by Opsens. RSVP Now!  Educational Lunch Symposium “Beyond FFR – Optimal Tools and Techniques for Coronary Physiology 2018” Sponsored by…

Read more

VISIT OPSENS AT THE 14TH ANNUAL C3 CONFERENCE

4 June 2018

Learn more about the benefits of OptoWire as a workhorse wire at the 14th annual Complex Cardiovascular Catheter Therapeutics: Advanced Endovascular and Coronary Intervention Global Summit (C3) conference by visiting us at the Opsens booth #207 or attend the complimentary educational lunch symposium with live case transmission sponsored by Opsens. RSVP Now!  Live Case Educational Lunch Symposium “Beyond FFR…

Read more

OPSENS APPLAUDS JAPANESE GOVERNMENT NEW REGULATION SUPPORTING DIAGNOSIS, SUCH AS FFR, BEFORE TREATMENT OF CORONARY STENOSIS

24 April 2018

Quebec City, Quebec, April 24, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) applauds Japan’s Ministry of Health, Labor and Welfare (“MHLW”) on its new regulation requiring the evaluation of any coronary stenosis prior to its treatment, specifically mentioning Fractional Flow Reserve (“FFR”) as a preferred assessment method. The MHLW recently revised medical…

Read more

OPSENS REPORTS Q2 2018 RESULTS – CONSOLIDATED PRODUCT SALES UP 44%

12 April 2018

Quebec City, Quebec, April 12, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the second quarter ended February 28, 2018. Highlights Consolidated product sales reached $5,352,000 compared with $3,710,000 for the same period last year, an increase of $1,642,000 or 44,3%; Fractional Flow Reserve (“FFR”) revenues reached $3,313,000…

Read more